MedTrace Logo

Neurocognitive Trajectories After BCMA CAR-T

NCT07740317 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-07-31

No results posted yet for this study

Summary

The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).

Conditions

  • Multiple Myeloma (MM)
  • CART Therapy
  • Refractory Multiple Myeloma (RRMM)

Interventions

OTHER

Standardized neurocognitive testing

Perform standardized neurocognitive testing at baseline and serially at 1-, 6-, and 12-months post-infusion.

Sponsors & Collaborators

  • Atrium Health Wake Forest Baptist

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Cindy Varga, MD · Atrium Health Levine Cancer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2029-11-30
Completion
2029-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07740317 on ClinicalTrials.gov